Collegium Pharmaceutical (COLL)
(Real Time Quote from BATS)
$31.99 USD
+0.21 (0.66%)
Updated Jul 15, 2024 02:56 PM ET
4-Sell of 5 4
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
COLL 31.99 +0.21(0.66%)
Will COLL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COLL
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for COLL
7 Biotech Stocks to Buy on the Dip: June 2024
IHF: Healthcare Dashboard For June
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
Collegium obtains six month extension of U.S. pediatric exclusivity for Nucynta
Jefferies upgrades Collegium to buy, cites upside related to LOEs